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Abstract
Background: CTLA-4 (Cytotoxic T-lymphocyte-associated protein 4) was the first immune checkpoint receptor
clinically targeted for use in cancer treatment. It is expressed exclusively on T-cells where its primary role is to
regulate the amplitude of the early stages of T-cell activation.1 Ipilimumab, a CTLA-4 blocking antibody, has been
widely used for the treatment of patients with high risk and metastatic melanoma. Given its mechanism of action
and consequent immune activation, the side effect profile of this drug greatly differs from that of standard cytotoxic
chemotherapy. Adverse events are from the most part immune-mediated, ranging from the more common, such as
rash and fatigue, to the less common, such as immune endocrinopathy and colitis.
Case presentation: We describe a case of immune-mediated thrombotic thrombocytopenic purpura (TTP) in a
68 year-old woman with high risk, stage III melanoma occurring after 3 cycles of adjuvant treatment with ipilimumab
as part of a clinical trial.
Conclusion: The range of immune-mediated adverse events during treatment with ipilimumab is wide and varied and
clinicians should have a high degree of suspicion when managing these patients.
Background
CTLA-4 (Cytotoxic T-lymphocyte-associated protein 4)
was the first immune checkpoint receptor clinically tar-
geted for use in cancer treatment. It is expressed exclusively
on T-cells where its primary role is to regulate the ampli-
tude of the early stages of T-cell activation [1]. Ipilimumab,
a CTLA-4 blocking antibody, has been widely used for the
treatment of patients with high risk and metastatic melan-
oma. Given its mechanism of action and consequent im-
mune activation, the side effect profile of this drug greatly
differs from that of standard cytotoxic chemotherapy. Ad-
verse events are from the most part immune-mediated,
ranging from the more common, such as rash and fatigue,
to the less common, such as immune endocrinopathy and
colitis [2]. Here, we describe a case of immune-mediated
thrombotic thrombocytopenic purpura (TTP) in a 68 year-
old woman with high risk, stage III melanoma occurring
after 3 cycles of adjuvant treatment with ipilimumab as part
of a clinical trial.
Case presentation
A 68 year old woman with stage III (pT3,N2,M0) ulcerated
spindle cell melanoma arising from the anterior aspect of
the right inferior turbinate mucosa was referred to our
melanoma clinic following definitive surgery. She agreed
and signed informed consent for participation in an adju-
vant study in which she was randomized to receive ipilimu-
mab, an anti-CTLA-4 antibody, at 10 mg/kg IV every
3 weeks for 4 cycles followed by maintenance therapy.
After the first cycle on 6/29/2015, she developed a
grade 1 pruritic rash and grade 1 ALT and AST elevation.
She received cycle 2 on July 20, 2015. Prior to receiving
cycle 3, transaminases increased further to grade 2. As a
result, cycle 3 was held and the patient was started on
prednisone 40 mg daily, and then tapered over 4 weeks
to 5 mg prednisone daily. The transaminase elevation
decreased from grade 2 to grade 1 and cycle 3 was
given on 8/24/15. During that time, she was found to
have an otitis externa and was prescribed topical cipro-
floxacin + dexamethasone drops from 8/24/2015 to 9/
10/2015, followed by oral clindamycin 300 mg TID
from 9/1/2015 to 9/11/2015. When seen on 9/9/2015, she
had grade 1 transaminase elevation, mild hyperglycemia,
* Correspondence: jose.lutzky@msmc.com
1Mount Sinai Comprehensive Cancer Center, Division of Hematology/
Oncology, 4306 Alton Road, Miami Beach, FL 33140, USA
Full list of author information is available at the end of the article
© The Author(s). 2017 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0
International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to
the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver
(http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
King et al. Journal for ImmunoTherapy of Cancer  (2017) 5:19 
DOI 10.1186/s40425-017-0224-7
normal renal function and a very mild microcytic anemia.
Platelet count and leukocyte count were normal.
On September 12, 2015, the patient developed profound
fatigue, decreased PO intake, nausea, vomiting, and two ep-
isodes of diarrheal stools. She presented to clinic on Sep-
tember 14, 2015. On the morning of her evaluation, she
complained of subjective fevers, altered mental status, and
worsening fatigue. Physical examination was remarkable for
a petechial rash over the chest and bilateral upper extrem-
ities. Laboratory evaluation demonstrated a severe micro-
cytic anemia and thrombocytopenia, with a hemoglobin of
6.8 g.dL and a platelet count of 7,000/uL. There was mild
leukocytosis with a WBC of 12,700/uL. Examination of the
peripheral blood smear (Fig. 1) showed marked anisocyto-
sis, severe decrease in platelets and the presence of abun-
dant schistocytes. Reticulocyte count was 5.41% (ULN
2.1%), serum LDH was 7,329 (ULN 618 U/L) and serum
haptoglobin was < 7.8 mg/dL (LLN 30 mg/dL). Acute renal
failure was characterized by oliguria, serum creatinine of
2.8 mg/dL and BUN 98 mg/dL. Serum transaminases
were mildly elevated. Serum bilirubin was 2.1 mg/dL
(ULN 1.3 mg/dL). Sedimentation rate was 75 mm/h
(ULN 30 mm/h) and serum C-reactive protein was
18.7 mg/L (ULN 3 mg/L). Blood cultures and disseminated
intravascular coagulation panel were negative. ADAMTS13
activity and inhibitor level were collected upon admission
to the hospital.
The patient was admitted to the intensive care unit
with a diagnosis of TTP. Solu-Medrol 1000 mg IV was
given for potential immune-mediated ipilimumab toxicity.
During hospitalization, the patient received the following
interventions: 5 courses of plasmapheresis with plasma ex-
change (9/16, 9/18, 9/19, 9/21, and 9/23), transfusion of 4
units of packed red blood cells, one unit of platelets, IV
gammaglobulin 2 g over two days (9/17 and 9/18), and ri-
tuximab 375 mg/m2 (9/24/15) (Fig. 2).
She improved clinically over the next several days
with reversal of renal failure, increased hemoglobin and
haptoglobin, normalization of LDH, and no recurrence
of mental status changes. By September 23, 2015, LDH,
haptoglobin, renal function, and platelet count were
normalized. She was given rituximab on 9/24/15 and
discharged home. Results of ADAMTS13, available on
day 7, revealed that ADAMTS13 activity was <3% (normal:
68-163% activity); ADAMTS13 inhibitor was 3.7H
(normal: <0.4 BEU).
Follow-up as an outpatient has shown no evidence of
TTP recurrence to the date of this report. She was per-
manently taken off ipilimumab and remains under close
monitoring for her high-risk melanoma.
Fig. 1 Peripheral blood smear demonstrating extensive presence
of schistocytes
Fig. 2 Vertical axis: values of serum creatinine, lactate dehydrogenase (LDH), hemoglobin, and platelet count during hospitalization in relation to
treatment with plasmapheresis, systemic corticosteroids, intravenous immunoglobulin (IVIG) and rituximab therapy. Horizontal axis: time in days
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Discussion
TTP is a primary thrombotic microangiopathy manifested by
consumptive thrombocytopenia, microangiopathic hemolytic
anemia (MAHA), and thrombosis. The underlying patho-
physiology of TTP is inhibition/inactivation of A Disintegrin
And Metalloprotease with ThromboSpondin type 1 repeats,
13 (ADAMTS13), a metalloprotease responsible for cleaving
large multimers of von Willebrand factor (vWF) into smaller
units. The increase in circulating large multimers of vWF
promotes platelet adhesion to areas of endothelial injury, par-
ticularly at arteriole-capillary junctions. As a consequence,
passing red blood cells are subjected to shear stress leading
to rupture of red blood cells within blood vessels, producing
hemolytic anemia and schistocyte formation. Reduced blood
flow due to thrombosis and cellular injury, results in end-
organ damage.
Many patients also present with neurological symptoms,
renal involvement, and fever [3, 4]. The classic pentad of
microangiopathic hemolytic anemia, thrombocytopenia,
neurologic symptoms, renal failure, and fever, albeit un-
common, has been traditionally considered to be diagnos-
tic of the disease.
While most cases of TTP are caused by ADAMTS13
autoantibodies, secondary TTP can also be caused by drugs,
bone marrow transplantation, and HIV infection. TTP may
occur due to a congenital deficiency of ADAMTS13
(Upshaw-Shulman syndrome) in about 1% of patients.
Current therapy is based on supportive care and plasma-
pheresis with plasma exchange to reduce circulating anti-
bodies against ADAMTS13 and to replenish blood levels
of the enzyme. Monoclonal therapy with the anti-CD20
antibody rituximab has recently shown efficacy [3–11].
Here, we describe the first report, to our knowledge,
of TTP associated with the use of ipilimumab. Although
it is possible that this patient could have had secondary
TTP from oral clindamycin therapy, a literature search
failed to demonstrate clindamycin-induced TTP. There
have been 2 cases reported of clarithromycin-induced
TTP [12]. Ciprofloxacin has been associated with TTP
but our patient was treated with topical ciprofloxacin
drops only [13].
Although rare, there have been reports of isolated
hemolytic anemia and thrombocytopenia related to Ipili-
mumab therapy [14]. Given the wide variety of immune
manifestations reported with the use of ipilimumab and
the autoimmune underlying nature of TTP, TTP should
be added to the list of possible immune-related adverse
events of ipilimumab and considered in the differential
diagnosis of ipilimumab-associated thrombocytopenia.
Conclusion
With the advent of immunotherapy as a dominant modal-
ity in cancer treatment, it is essential for clinicians to be
able to quickly identify and treat the common associated
and rare immune related toxicities. This requires a high
degree of clinical suspicion when addressing patient re-
ported signs and symptoms.
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